2[2]Lind P.131I whole body scintigraphy in thyroid cancer patients[J].Q J Nucl Med,1999,43(1):188-194
3[3]Samuel AM,Rajashekharrao B,Shah DH.Pulmonary metastases in children and adolescents with well-differentiated thyroid cancer[J].J Nucl Med,1998,39(6):1531-1536
4[5]Nahas Z,Goldenberg D,Fakhry C,et al.The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma[J].Laryngo Scope,2005,115(2):237-243
5[6]Chung JK,Park YJ,Kim TY,et al.Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation[J].Clin Endocrinol(Oxf),2002,57(2):215-221
6Boerman O C, Oyen W J G, Corstens F H M. Between the scylla and charybdis of peptide radionuclide therapy:hitting the tumor and saving the kidney[J]. Eur J Nucl Med, 2001, 28:1447-1449.
7Forssell-Aronsson E, Bernhardt P, Nilsson O, et al. Biodistribution data from 100 patients iv. injected with 111In-DTPA-D-pheloctreotide [J]. Acta Oncol, 2004, 43(5): 436-442.
8Bushnell D, Menda Y, O' Dorisio T, et al. Effect of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-octreotide (SMT487[Octreo TherTM])treatment[J]. Cancer Biother Radiopharm,2004, 19(1): 35-41.
9Pauwels S, Barone R, Walrand S, et al. Practical dosimetry of peptide receptor radionuclide therapy with 90Y-labeled somatostatin analogs[J]. J Nucl Med, 2005, 46(1 suppl): 92S-98S.
10Moll S, Nickeleit V, Mueller-Brand J, et al. A new cause of renal thrombotic microangiopathy: Yttrium-90-DOTATOC internal radiotherapy[J]. Am J kidney Dis, 2001,37(4): 847-851.
